Welcome to our dedicated page for YULONG ECO MATERIALS news (Ticker: YECO), a resource for investors and traders seeking the latest updates and insights on YULONG ECO MATERIALS stock.
YULONG ECO MATERIALS LTD, now known as EV Biologics Corp, is a biotechnology company based in Wyoming, USA. Their focus lies in developing stem cell-derived exosome-based therapeutic products and biocompatible formulations to enhance bioactivity and potency. Through advanced biomanufacturing, bioengineering, and bioinformatics, they aim to optimize nanoparticle-based biologics for various clinical applications, including regenerative medicine and longevity.
EV Biologics also owns Excyte, a subsidiary focused on developing biotherapeutics from living cells. Their innovative approach utilizes nanotherapeutic platforms to deliver bioactive molecules to target cells, combat aging, and promote longevity. With a strong emphasis on research and development, as well as collaboration with commercial partners, EV Biologics is poised to revolutionize modern medicine with their groundbreaking therapeutic solutions.
EV Biologics Corp. (OTC PINK:YECO) has confirmed that shareholders of record on July 30, 2021 will receive an NFT Warrant Dividend. For every 100 shares held, shareholders will receive one Warrant, each exercisable for an NFT valued at $300, with a 90-day exercise window ending on October 28, 2021. Shareholders must hold shares for several days post-record date to ensure eligibility, and those with fewer than 100 shares will not qualify. The Company aims to uplist to OTCQX by year-end.
EV Biologics Corp (OTC PINK:YECO) has partnered with Lonza Cell Bio Services to establish a custom cell isolation for a novel clonal master cell bank. This initiative will aid the production of therapeutically active extracellular vesicles (EVPs). CEO Daniel Mckinney emphasized that this collaboration is pivotal for their first cell line generation and will support the development of engineered EVP therapeutics. The isolated cells will enhance gene expression analysis and facilitate a continuous EVP production process, aimed at addressing various clinical indications.
EV Biologics Corp (OTC PINK: YECO) announced an NFT dividend, offering one warrant for every 100 shares held. Each warrant can be exercised for an NFT valued at $300, with a 90-day period for shareholders to redeem it, ending October 28, 2021. Only shareholders of record as of July 30, 2021, qualify for this special dividend. The NFT is in production, and a preliminary image will be revealed soon. The company plans to up-list to OTCQX by year-end 2021.
EV Biologics Corp. (OTC PINK: YECO) has signed a Letter of Intent with Lonza Cell & Gene Therapy for process development in biomanufacturing a novel therapeutic composition. This includes extracellular vesicles and factors from mesenchymal stromal cells, enhancing their potential as cell-free therapeutics for various diseases. The collaboration aims to leverage Lonza's expertise in cGMP manufacturing, ensuring compliance with regulatory standards for future clinical trials. EV Biologics is focused on optimizing the therapeutic activity of stem cell-derived products to support preclinical research and advanced clinical applications.
EV Biologics Corp (OTC PINK: YECO) announced a special NFT dividend of 1 NFT for every 100 shares of common stock, effective for shareholders of record on July 30, 2021. The company aims to leverage these NFTs—acquired for $21.68 million—as a balance sheet asset valued at $10.63 million. CEO Daniel McKinney stated that he, along with another large shareholder, will not receive their allotted NFTs, retaining them within the company. EV Biologics plans to apply for an OTCQX listing before the end of 2021.
EV Biologics Corp (OTC PINK:YECO) has announced a unique dividend strategy, distributing one Non-Fungible Token (NFT) for every 100 shares held as of the record date, July 30, 2021. This special dividend targets shareholders who own at least 100 shares, with each NFT valued at $300, representing a total investment of $21,675,900 for 72,253 NFTs acquired from MS Token LLC. CEO Daniel Mckinney highlighted this as a historic event for public companies, linking it to the company's commitment to regenerative technologies.
EV Biologics Corp (OTC PINK:YECO) has announced its compliance with OTC Markets, achieving a Pink Current status, which enhances trading accessibility for brokers. CEO Daniel Mckinney expressed satisfaction with this development as the company shifts focus towards innovative regenerative biologics, targeting a secured funding of up to $5 million for new exosome-related projects. Additionally, EV Biologics plans to apply for a name change and intends to up-list to OTCQX by year-end.
Exosomes are highlighted for their therapeutic potential in treating various diseases, including cancer.
EV Biologics Corp. (OTC PINK: YECO) updates shareholders on its name change process submitted to FINRA. The company transitioned from the Cayman Islands to Wyoming, completing the necessary filings by May 2019. Despite the name change being effective globally since July 2020, additional document requests from FINRA have delayed the finalization. The company emphasizes that these requests, necessitating notarization, are standard but hindered by COVID-related notary shortages. Once completed, a new trading symbol will be assigned, enhancing investor recognition.
EV Biologics Corp (OTC PINK:YECO) announced a director's loan agreement for up to $5 million aimed at developing a novel exosome-producer cell line and producing therapeutic exosomes for preclinical research. The funding will facilitate the generation of a master cell bank with potential applications in various clinical settings. The company plans to produce research-grade exosomes from induced pluripotential stem cells, enhancing native exosome bioactivity. CEO Daniel Mckinney expressed ambitious goals to revolutionize medicine. EV Biologics aims to up-list to a mainboard exchange by the end of 2021.
EV Biologics Corp (OTC PINK: YECO) has approved a scalable biomanufacturing plan for exosome biopharmaceuticals during its Q1 R&D meeting. The company aims to establish a cGMP process utilizing optimized producer cells for extracellular vesicle (EV) production. CEO Daniel Mckinney emphasized that this initiative will facilitate reliable production for clinical studies. The company plans to initiate preclinical studies of its exosome candidates in Q4 2021. With 7.22 million shares outstanding and a float of 1,016,375 shares, EV Biologics is positioning itself in the biopharmaceutical market.
FAQ
What is the market cap of YULONG ECO MATERIALS (YECO)?
What is YULONG ECO MATERIALS LTD known for?
What is EV Biologics Corp's focus areas?
What subsidiary does EV Biologics Corp own?
How does EV Biologics Corp plan to revolutionize modern medicine?
What sets EV Biologics Corp apart in the biotechnology industry?
What clinical applications does EV Biologics Corp target?
Where is EV Biologics Corp based?
What recent achievements has EV Biologics Corp celebrated?
What future goals does EV Biologics Corp aim to achieve?
How does EV Biologics Corp approach research and development?
